Lupin to file its first biosimilar etanercept for approval in Japan in 2017

MD Nilesh Gupta says Lupin is developing a pipeline of four biosimilars focussed on regulated markets

Viswanath Pilla
First Published12 Aug 2016, 12:53 AM IST
Lupin is currently one of the largest generic drug companies in Japan.<br />
Lupin is currently one of the largest generic drug companies in Japan.

Hyderabad: Lupin Ltd., India’s third largest drug maker plans to file its first biosimilar, etanercept, for approval in Japan, the world’s second largest market for medicines next year. This will be followed by Europe and the US, as it tries to catch up with other Indian rivals like Biocon Ltd and Dr.Reddy’s Laboratories Ltd who had the first mover advantage.

Biosimilars are copies of complex biological drugs made from living cells and cannot be identically replicated.

Etanercept is the biosimilar version of US-based Amgen Inc.’s drug Enbrel with global sales of $5.36 billion. It is used to treat five chronic inflammatory conditions, including rheumatoid arthritis and plaque psoriasis.

“It (etanercept) is in phase-III trial – plan is to be able to file next year for Japan, Europe and still need to talk to (US) FDA (Food and Drug Administration),” said Nilesh Gupta, managing director of Lupin in a telephone interview.

Gupta said his company is developing a pipeline of four biosimilars focussed on regulated markets, without disclosing specific details of those products and timelines.

Lupin formed a joint venture with Japan-based Yoshindo Inc. two years ago to handle clinical trials, regulatory filings and obtain marketing authorizations for certain biosimilars including etanercept in Japan.

Lupin is currently one of the largest generic drug companies in Japan.

The global biosimilar market is predicted to have sales of $25 billion by 2020, according to a 2014 Thomson Reuters report. Developed markets account for a lion’s share.

Catch all the Industry News, Banking News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates.MoreLess
First Published:12 Aug 2016, 12:53 AM IST
HomeindustrymanufacturingLupin to file its first biosimilar etanercept for approval in Japan in 2017

Most Active Stocks

Indian Oil Corporation

166.90
03:58 PM | 12 JUL 2024
-7.6 (-4.36%)

Tata Steel

168.70
03:58 PM | 12 JUL 2024
-0.3 (-0.18%)

Bharat Electronics

333.30
03:59 PM | 12 JUL 2024
-2.25 (-0.67%)

Wipro

560.05
03:56 PM | 12 JUL 2024
25.7 (4.81%)
More Active Stocks

Market Snapshot

  • Top Gainers
  • Top Losers
  • 52 Week High

KPIT Technologies

1,864.00
03:57 PM | 12 JUL 2024
154.25 (9.02%)

Inox Wind

171.90
03:59 PM | 12 JUL 2024
13.85 (8.76%)

Zensar Technologies

768.20
03:29 PM | 12 JUL 2024
50.45 (7.03%)

Coforge

5,950.05
03:29 PM | 12 JUL 2024
386.65 (6.95%)
More from Top Gainers

Recommended For You

    More Recommendations

    Gold Prices

    • 24K
    • 22K
    Bangalore
    74,087.00382.00
    Chennai
    73,942.00-780.00
    Delhi
    74,014.00309.00
    Kolkata
    74,377.00-345.00

    Fuel Price

    • Petrol
    • Diesel
    Bangalore
    102.86/L0.00
    Chennai
    100.85/L0.10
    Kolkata
    104.95/L0.00
    New Delhi
    94.72/L0.00
    OPEN IN APP
    HomeMarketsloanPremiumMint Shorts